Pharmaceuticals

Pulmonary Drugs Market Analysis With Focus On Growth Potential And Future Outlook

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Pulmonary Drugs Market During 2026–2030?

The pulmonary drugs market has demonstrated substantial growth over recent years. Its valuation is anticipated to climb from $56.98 billion in 2025 to $60.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.4%. This past expansion can be primarily attributed to factors including increasing asthma prevalence, rising COPD incidence, the growth of urban air pollution, the expansion of inhalation drug delivery, and enhanced diagnosis of respiratory diseases.

The pulmonary drugs market is anticipated to experience robust expansion in the coming years. This market is projected to reach $74.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this growth during the forecast period include an expanding aging population, the proliferation of biologic pulmonary drugs, wider adoption of precision respiratory medicine, a rise in smoking-related illnesses, and enhanced availability of inhaled treatments. Key trends anticipated for the forecast duration encompass a growing embrace of targeted respiratory therapies, the development of combination inhalation treatments, an increased emphasis on managing diseases for the long term, the broadening scope of biologic-based pulmonary medications, and a movement towards individualized respiratory care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Which Drivers Are Supporting The Pulmonary Drugs Market Growth?

The expanding occurrence of respiratory illnesses is projected to fuel the expansion of the pulmonary drugs market in the future. Respiratory disorders are defined as health conditions impacting the lungs and airways, thereby hindering regular breathing and the exchange of oxygen. These disorders are on the rise, primarily attributed to the widespread increase in smoking, which results in lung damage and chronic ailments. Pulmonary drugs are vital in addressing respiratory disorders, as they enhance lung function, decrease inflammation, and alleviate airway blockages, facilitating improved respiration. As an illustration, in May 2025, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, the age-adjusted prevalence of COPD among adults 18+ stood at 3.8%, with women exhibiting higher rates (4.1%) compared to men (3.4%). The occurrence of COPD sharply escalated with advancing age, climbing from 0.4% in adults 18–24 to 10.5% in individuals 75 and older. Consequently, the surge in respiratory diseases is propelling the growth of the pulmonary drugs market.

Which Segments Define The Pulmonary Drugs Market Segment Structure?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Which Trends Are Shaping Growth In The Pulmonary Drugs Market?

Leading companies within the pulmonary drugs market are concentrating on therapeutic advancements, such as the combined PDE3 and PDE4 inhibition delivered via inhalation, aiming to merge bronchodilator and non-steroidal anti-inflammatory actions into a single compound for the ongoing management of chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition simultaneously promotes airway relaxation and reduces lung inflammation, addressing persistent COPD symptoms more effectively than existing treatments and simplifying administration without the need for intricate inhalation techniques. As an illustration, in June 2024, Verona Pharma plc, a biopharmaceutical company based in the UK, secured U.S. FDA approval for Ohtuvayre (ensifentrine), which is the first inhaled treatment with this dual-mechanism characteristic in over 20 years. Administered through a standard jet nebulizer, Ohtuvayre offers both bronchodilator and anti-inflammatory advantages in a single dose, proving its clinical effectiveness as a standalone therapy and when combined with other maintenance treatments in the Phase 3 ENHANCE trials, with availability through specialty pharmacies in the U.S. projected by the third quarter of 2024.

Who Are The Established Players Within The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Get The Full Pulmonary Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Which Region Has The Greatest Market Share In The Pulmonary Drugs Market?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pulmonary Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795